Amevive (Alefacept) 

Mfg:  Biogen

Indication(s):  Treatment of adult patients with moderate or severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

Administration:  7.5 mg given once weekly as an I.V. bolus or 15 mg given once weekly as an intramuscular (IM) injection (12 weekly injections recommended).  

Pharmacology:  An immunosuppresive which works by interference with lymphocyte activation by specifically binding to the lymphocyte antigen, CD2, and inhibiting LFA-3/CD2 interaction.

WebRx Editorial Notes:  The effects of renal or hepatic impairment on pharmacokinetics of alefacept have not been studied.  Excessive immunosuppression may occur if alefacept is used in patients also receiving other immunosuppressive agents or phototherapy.

 

2004 WebRx Pharmacy Palace